<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03162419</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-ACLF-01</org_study_id>
    <nct_id>NCT03162419</nct_id>
  </id_info>
  <brief_title>To Assess the Efficacy of High-Volume Plasma Exchange and GCSF Versus GCSF Alone in Patients of Acute on Chronic Liver Failure (ACLF).</brief_title>
  <official_title>To Assess the Efficacy of High-Volume Plasma Exchange and GCSF Versus GCSF Alone in Patients of Acute on Chronic Liver Failure (ACLF)-A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design-Open label randomized controlled trial

      Study period-2 years

      Study population-All patients of ACLF admitted to ILBS for a period of two years from Feb
      2017 to Dec 2018

      All the patients of ACLF will receive standard medical therapy and will be randomized within
      48 hours of admission into three groups after screening for exclusion and inclusion
      criteria.(1:2:2) Group A-Standard Medical Therapy only Group B-Standard Medical therapy +
      Plasma exchange + GCSF Group C-Standard Medical Therapy + GCSF
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">April 25, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant free survival</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in biochemical parameter which is defined as &gt; 20% reduction from baseline in both groups</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in biochemical parameter which is defined as &gt; 20% reduction from baseline in both groups</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in clinical parameters which is defined as &gt; 20% reduction from baseline in both groups</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in clinical parameters which is defined as &gt; 20% reduction from baseline in both groups</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in APACHEII (by 2 points )</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in MELD (by 2 points )</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in SIRS by 2 points</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in SOFA (by 2 points )</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new onset sepsis and SIRS in both groups.</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of therapy in both groups</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>Standard Medical Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medical Therapy + Plasma exchange + GCSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in group B shall be given GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28 along with alternate day high volume plasma exchange sessions till a maximum of ten sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medical Therapy + GCSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in this will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Medical Therapy</intervention_name>
    <description>The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.</description>
    <arm_group_label>Standard Medical Therapy</arm_group_label>
    <arm_group_label>Standard Medical Therapy + Plasma exchange + GCSF</arm_group_label>
    <arm_group_label>Standard Medical Therapy + GCSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma Exchange</intervention_name>
    <description>High volume plasma exchange sessions till a maximum of ten sessions.</description>
    <arm_group_label>Standard Medical Therapy + Plasma exchange + GCSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GCSF</intervention_name>
    <description>The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28</description>
    <arm_group_label>Standard Medical Therapy + Plasma exchange + GCSF</arm_group_label>
    <arm_group_label>Standard Medical Therapy + GCSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - All consecutive patients in age group of 18-70 years with acute on chronic liver failure
        as defined by APASL criteria shall be included in the study.Only those patients who wish to
        be enrolled in the trial shall be included in the study.

        Exclusion Criteria:

          1. Steroid eligible patients with severe alcoholic hepatitis

          2. Cirrhosis of liver with previous history of decompensation

          3. Patients with severe cardiopulmonary disease

          4. Pregnancy

          5. Human Immmunodeficiency Virus infection

          6. Hepatocellular carcinoma or extrahepatic malignancy

          7. Chronic renal insufficiency on treatment with haemodialysis

          8. Uncontrolled bleed or patients in disseminated intravascular coagulopathy

          9. Patient with expected survival of less than 48 hours

         10. Patients with moderate-severe acute respiratory distress syndrome

         11. Hemodynamic instability with noradrenaline requirement of more than &gt;0.5ug/kg/min or
             requirement of dual vasopressors

         12. Patients with leukemoid reaction or total leucocyte count &gt; 40,000/mm3

         13. Patients diagnosed with Hemophagocytic Lymphohistiocytosis

         14. Patients with known hypersensitivity to Granulocyte colony stimulating factor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Manjul Mishra, MD</last_name>
    <phone>01146300000</phone>
    <email>manjul2883@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Lactulose</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

